Open Access Green as soon as Postprint is submitted to ZB.
Divergent associations of height with cardiometabolic disease and cancer: Epidemiology, pathophysiology, and global implications.
Lancet Diabet. Endocrinol. 4, 457-467 (2016)
Among chronic non-communicable diseases, cardiometabolic diseases and cancer are the most important causes of morbidity and mortality worldwide. Although high BMI and waist circumference, as estimates of total and abdominal fat mass, are now accepted as predictors of the increasing incidence of these diseases, adult height, which also predicts mortality, has been neglected. Interestingly, increasing evidence suggests that height is associated with lower cardiometabolic risk, but higher cancer risk, associations supported by mendelian randomisation studies. Understanding the complex epidemiology, biology, and pathophysiology related to height, and its association with cardiometabolic diseases and cancer, is becoming even more important because average adult height has increased substantially in many countries during recent generations. Among the mechanisms driving the increase in height and linking height with cardiometabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways. These pathways are thought to be activated by overnutrition, especially increased intake of milk, dairy products, and other animal proteins during different stages of child development. Limiting overnutrition during pregnancy, early childhood, and puberty would avoid not only obesity, but also accelerated growth in children-and thus might reduce risk of cancer in adulthood.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
16.320
4.364
64
67
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Growth-factor-i; Boyd-orr Cohort; Ischemic-heart-disease; British Womens Heart; Of-the-literature; Body-mass Index; Adult Height; Prostate-cancer; Mendelian Randomization; Insulin-resistance
Language
Publication Year
2016
HGF-reported in Year
2016
ISSN (print) / ISBN
2213-8587
e-ISSN
2213-8595
Quellenangaben
Volume: 4,
Issue: 5,
Pages: 457-467
Publisher
Elsevier
Publishing Place
New York
Reviewing status
Peer reviewed
POF-Topic(s)
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502400-002
G-502400-001
G-502400-001
WOS ID
WOS:000375107800026
PubMed ID
26827112
Erfassungsdatum
2016-02-03